A bench trial began June 24, 2026, in Alameda County Superior Court over California’s allegations that two national pregnancy resource networks made false claims about reversing the effects of mifepristone, the first pill used in medication abortion. The state is suing Heartbeat International, a Columbus, Ohio-based organization, and RealOptions Obria Medical Clinics, which operates four locations in the San Francisco Bay area.

California Attorney General Rob Bonta filed the complaint in September 2023, contending that the defendants disseminated misleading statements about a treatment intended to reverse abortion pill effects. The state argues that no credibly designed medical study has verified the efficacy of abortion pill reversal, the procedure by which a second hormone is administered after mifepristone to attempt to continue a pregnancy.

The Legal Claim and Penalties

The state seeks civil penalties of $2,500 per violation under California business and professional codes. Attorneys defending the centers estimate the potential total liability at more than $20 million, should the state prevail on all counts.

The trial operates as a bench trial, meaning the judge will determine both the facts and the law without a jury. The Thomas More Society, a religious liberty nonprofit defending the organizations, announced the trial’s opening on July 23.

The Dispute Over Speech and Science

At issue is whether claims made by the pregnancy centers about abortion pill reversal constitute unlawful false advertising or protected speech on a contested medical question. California permits doctors to offer the treatment; the dispute centers on how the procedure is marketed and what statements accompany its promotion.

Peter Breen, representing the defendants, cast the case as one affecting vulnerable women. “If Bonta succeeds, those moms go unaided and their babies likely die,” Breen said, framing the lawsuit as an obstacle to counseling pregnant women who wish to continue their pregnancies.

Paul Jonna, also defending the centers, emphasized constitutional concerns. “The First Amendment forbids government from suppressing speech it doesn’t like, especially on deeply contested scientific debates,” he said, positioning the case as a free speech matter rather than a simple consumer protection dispute.

Medical and Policy Background

Abortion pill reversal is a legitimate medical procedure under California law. Doctors in the state remain free to prescribe the progesterone-based treatment to patients who have taken mifepristone and wish to attempt to continue their pregnancies. The state’s objection is not to the treatment itself but to what it characterizes as unsubstantiated promotional claims.

The medical evidence on abortion pill reversal remains disputed. Major medical organizations, including the American College of Obstetricians and Gynecologists, have stated that the evidence base for the procedure is limited. Proponents, however, point to published studies and clinical experience suggesting the treatment can be effective in some cases.

What Comes Next

The trial will proceed in Alameda County court. The judge’s decision may turn partly on expert testimony about the state of medical evidence and partly on whether marketing materials cross the line from opinion or incomplete assertion into demonstrable falsehood under California consumer protection law.

The case touches on a broader tension: how courts should treat health claims on matters where the scientific community itself remains divided, and how state consumer protection authority intersects with free speech rights and the freedom of doctors and counselors to discuss controversial treatment options with patients or potential patients.